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Abstract 
 P. aeruginosa 1244 pilin is covalently modified with a 
carbohydrate moiety, which is structurally similar to the 
lipopolysaccharide (LPS) O-antigen repeating unit. Studies were 
conducted using transmission electron microscopy and scanning 
electron microscopy with the monoclonal glycan-specific 
antibody, 11.14, to determine the location of the glycan.  It 
was found that the glycan is evenly distributed over the entire 
surface of the pilin fiber and not restricted to the tip.  The 
immunogenicity of the pilin glycan was also studied.   Rabbits 
were immunized with pure LPS-free pili to determine if the pili 
produce anti-LPS antibodies.  The serum obtained from the 
rabbits was analyzed using ELISA assay and was found to have a 
high titer of IgG anti-LPS antibodies.  Mice were also immunized 
with pure reaggregated pili to determine a titer level to IgG, 
IgA, and IgM antibodies.  A response was seen with the IgM 
antibodies in the serum, however the levels were similar to the 
sham-immunized mice.  Protection studies were also conducted 
using the rabbit serum to determine if there was serum 
resistance or PMN killing.  There was no serum sensitivity or 
PMN killing detected in the strains tested.   
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I.  Introduction 
 
 A.  General characteristics of Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa, a member of the family 
Pseudomonadacae (Stanislavsky, 1997), is a rod-shaped Gram-
negative bacterium.  It is considered an aerobic opportunistic 
pathogen (Odeh, 2000). P. aeruginosa was first isolated by 
Gessard in 1882 and named Bacillus pyocyaneus (Lyczak et al, 
2000). 
P. aeruginosa is ubiquitous to the environment due to 
several factors. The first factor is its ability to utilize many 
environmental compounds as energy sources which allows it to 
colonize in areas with limited resources. Secondly, it has the 
ability to colonize multiple environmental niches due to its 
large genome size and genetic complexity (Stover et al, 2000). 
P. aeruginosa is relatively easy to identify in the 
laboratory.  The bacterium grows on many types of media such as 
LB (Luria Bertani), CAYE, and TSA.  Its unique characteristic in 
the laboratory is the production of pyocyanin, a water-soluble 
green phenazine pigment which causes a green color to the 
culture medium (Odeh, 2000). 
B.  Medical Aspects of P. aeruginosa 
Since P. aeruginosa is an opportunistic pathogen, it 
frequently causes infections in immunocompromised individuals.  
P. aeruginosa was ranked the second most frequent pathogen in 
 1
surgery and third in medicine.  P. aeruginosa is among the most 
frequently isolated organisms from pus, sputum, blood, and other 
clinical material of patients with Gram-negative hospital 
infections (Stanislavsky and Lam, 1997). It’s ability to adapt 
to many types of environments with sparse nutrients makes it a 
dangerous pathogen. 
P. aeruginosa is a common cause of infection among burn 
victims.  These patients have very little skin over their 
wounds, therefore, eliminating the protective barrier against P. 
aeruginosa.  A burn wound with a P. aeruginosa infection is 
characterized by a blue-green color, caused by the pigment 
pyocyanin released in subcutaneous fat tissue (Pruitt et al., 
1998).  Pseudomonas aeruginosa may appear in the patients’ stool 
initially from ingested foods and then autoinoculate the burn 
wounds located on the body (Bodey et al., 1983).  Currently, an 
infected burn wound is being treated with an application of 
citric acid which seems to eliminate an infection of P. 
aeruginosa quicker and stimulates the formation of granulation 
tissue which is commonly seen within freshly healing tissue 
(Nagoba et al., 1998).  This new aggressive treatment varies 
from the normal protocol which is betadine, 0.5% silver nitrate, 
or silver sulfadiazine creams (Bodey et al., 1983).  
P. aeruginosa is also a common cause of corneal infections 
in humans.  The bacterium will usually only be found isolated in 
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contact-lens wearers with keratitis because the ability to 
adhere to healthy corneal epithelial cells is extremely low 
(Lomholt et al., 2001).  Small scratches on the cornea caused by 
improper use of contact lenses give P. aeruginosa opportunity to 
infect the wounded area.  The source of bacteria is usually the 
contact lens storage cases, commercial solutions, and various 
household surfaces (Micallef et al., 2000).  Corneal infections 
with P. aeruginosa can also begin by aerosol exposure from 
mechanical ventilation that some patients need as part of their 
course of treatment (Smulders et al., 1999).  Mechanical 
ventilation treatment can also cause pneumonia.  P. aeruginosa 
can also colonize the cornea in areas of tissue damage which 
expose various receptors for adhesion (Hazlet et al, 1986).  
Common adhesins for corneal infection of P. aeruginosa are 
pilin, alginate, and the ADP-ribosylating toxin exoenzyme S 
which gives the bacterium an advantage over other bacteria 
species (Fleizig et al., 1996).  Recently described by Evans et 
al., (2002) lipopolysaccharide (LPS) plays a major part in 
causing infection of the cornea.  LPS has an interactive role 
with the internalization survival by protection against 
bacterial killing (Evans et al., 2002). 
P. aeruginosa is generally associated with cystic fibrosis, 
the most common lethal autosomal recessive disorder among 
caucasians.  It is a genetic disease which causes the body to 
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produce an abnormally thick, sticky mucus due to a mutation in 
the chloride channel protein called cystic fibrosis 
transmembrane conductance regulator (CFTR).  The core 
polysaccharide of LPS attaches the bacteria to CFTR.  P. 
aeruginosa bound in this manner can then invade them.  The thick 
mucous prevents the bacteria from being expelled which leads to 
life-threatening lung infections.  As the result from abnormal 
salt and water regulation, the thick mucus accumulates in the 
intestines and lungs, therefore, causing malnutrition, frequent 
respiratory problems, difficulty breathing, and lung damage.  
One of every 3900 live births of all Americans have cystic 
fibrosis.  The average life span of these babies is 
approximately 33 years.  These individuals are taught to wash 
their hands often to avoid all types of infections including P. 
aeruginosa.  It is probably the most prevalent bacterium found 
in cystic fibrosis patients causing death in over 90% of 
individuals with CF (Darling and Evans, 2003).  Most patients 
are infected with the non-mucoidal strains of P. aeruginosa, 
however as the infection progresses, the bacterium transitions 
to the mucoidal strain.  This leads to a poor prognosis because 
at this point, P. aeruginosa can colonize the mucosal membrane 
and cause chronic lung infections.  A murine model of chronic 
mucosal colonization by P. aeruginosa was developed to evaluate 
the prevention of the initial bacterial colonization (Pier, 
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1992).  In the future, this model may provide evidence for an 
effective therapeutic solution.  Maintenance chemotherapy is 
currently the only prolongment for CF patients.  With this 
treatment, ninety percent of the patients now have the ability 
to survive at least ten more years after the onset of a chronic 
infection (Hoiby, 1995). 
Research is still being done on new treatments for P. 
aeruginosa infections in the lungs of cystic fibrosis patients.  
Nitric oxide (NO) production is being closely examined to 
determine the effects on P. aeruginosa in the lungs of both 
normal and diseased.  The third isoform of NO synthase (NOS), 
inducible NOS (iNOS), is expressed after an inflammatory 
stimulus in the lungs of normal individuals and produces NO that 
generates antimicrobial activity against a number of bacteria, 
fungi, protozoans, and helminthes (Fang, 1997).  It was found 
that cystic fibrosis patients have a lack of epithelial iNOS 
located in their lungs (Kelley et al., 1998).  The study looked 
at whether P. aeruginosa is affected by NO production from iNOS.  
The investigators found that NO production did reduce the amount 
of P. aeruginosa that adhered to human bronchial epithelial 
cells and enhanced killing of internalized bacteria (Darling and 
Evans, 2003) This would lead us to think that the lack of 
epithelial iNOS in cystic fibrosis patients does contribute to 
P. aeruginosa infections and colonization.  Future aims for this 
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study is to create an aerosol agent that would increase the 
amount of iNOS in the lungs of cystic fibrosis patients. 
P. aeruginosa can infect many different parts of the body.  
The skin when it is abnormal and unhealthy is a part of the body 
that P. aeruginosa is able to colonize.  When the skin is wet 
constantly, burned, or lacerated, P. aeruginosa will usually 
begin to colonize the weakened area. Other possible infection 
areas are corneal ulcers in the eyes, otitis externa in the 
ears, nose, throat, Pseudomonas meningitis of the brain and 
spinal cord, endocarditis in the heart, enteritis in the 
gastrointestinal tract, urinary tract infections, ostermyelitis 
in bones and joints, and septicemia of the blood.  Most 
individuals who become infected by P. aeruginosa are 
immunocompromised.  Since these patients’ primary host defenses 
such as complement and PMN’s (poly-morpho-nuclear leukocytes) 
are weakened by cancer or disease, they cannot fight off the 
bacterial infection like healthy individuals would be able to do 
(Bodey et al., 1983). 
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C.  Virulence Factors 
 P. aeruginosa is such an effective pathogen due to the 
number of virulence factors it possesses.  The pathogenesis of 
P. aeruginosa can be divided into three stages: bacterial 
attachment and colonization, local invasion, and dissemination 
with systemic disease (Odeh & Quinn, 2000).  It remains an 
effective and lethal bacterium due to its resistance to many 
antibiotics and antimicrobial treatments.  P. aeruginosa is one 
of few nonfermentative bacteria that falls into each of the 
three classes of antibiotic resistance; intrinsic resistance, 
acquired resistance, and genetic resistance.  Intrinsic 
resistance consists of the resistance that occurs on the average 
strain of a given species without antibiotic exposure.  Acquired 
resistance is observable when a strain gains resistance but has 
no genetic alteration.  Genetic resistance involves the stable 
acquisition of new genetic material, either through mutation of 
an existing gene product or through gaining of a drug resistance 
plasmid (Hancock, 1998). 
 As a Gram-negative bacterium, P. aeruginosa possesses 
lipopolysaccharide (LPS) in its outer membrane.  LPS, as shown 
in figure 1, is a nonpilus adhesin which is composed of a 
hydrophobic lipid A region, a hydrophilic core region, and then 
a series of O-specific repeating sugars that provides protection 
and antigenic variability for the bacterium during an infection.  
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The lipid A portion of LPS secures P. aeruginosa to the host and 
is the toxic component of LPS.  LPS attaches to cystic fibrosis 
transmembrane conductance regulator (CFTR) which is a chloride 
channel protein.  Studies have shown that the attachment of CFTR 
to LPS causes CFTR to initiate the innate or natural immunity 
(Schroeder et al., 2002).  When a patient has cystic fibrosis, 
the lipid A structure can influence two parts of the 
pathogenesis.  First, it is able to enhance bacterial survival 
or colonization due to the resistance lipid A gives against 
cyclic adenosine monophosphates (cAMP) and other membrane active 
components of the innate immune system.  Secondly, on the other 
end of the spectrum, lipid A is also known to begin an 
inflammatory response with specific CF lung (Ernst et al., 
1999). 
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Figure 1: The structure of LPS 
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 P. aeruginosa has many exotoxins to harm the host cells. 
ExoS has ADP-ribosylating activity for a number of host cell 
proteins including the intermediate filaments of cytoskeleton 
and GTP-binding proteins which are involved in host cell signal 
transduction systems.  ExoS is delivered to the host cells 
through the type III secretion system.  Cytotoxin ExoS has two 
functional domains which aid in its toxicity.  Intracellular 
expression of the amino-terminal domain causes disruption of 
actin while the expression of the carboxyl-terminal domain has 
FAS-dependent ADP-ribosyltransferase activity and is cytotoxic 
to eukaryotic cells (Pederson et al., 1999).  ExoS has been 
found to cause the induction of the apoptotic pathway in 
epithelial and fibroblast cell lines (Kaufman et al., 2000).  
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ExoT, another of the exoenzymes, has been found to have a lower 
molecular weight than ExoS even though it possesses the same 
function as ExoS (Liu et al., 1997).  The final two exoenzymes, 
ExoU (Finck-Barbancon et al., 1997) and ExoY (Yahr et al., 
1998), have unclear functions and mechanisms at this time. 
 Another toxin that is secreted using type II secretion by 
P. aeruginosa is exotoxin A.  Similar to exoenzyme S, exotoxin A 
ADP-ribosylates elongation factor-2, which is essential in 
protein synthesis.  After binding to the 300kDa glycoprotein 
receptor, the enzymatic portion is internalized by endocytosis 
which then causes negative effects on the host cell.  Exotoxin A 
is thought to be the most toxic virulence factor produced by P. 
aeruginosa.  However, studies are finding the polyclonal and 
monoclonal antibodies to small areas of exotoxin A can aid in 
passive immunization or topical treatment of burn patients 
(Elzaaim et al., 1998). 
 Among the virulence factors that allow P. aeruginosa the 
ability to cause invasive disease are extracellular proteases.  
There are various proteases that inhibit the function of 
neutrophils, monocytes, natural killer cells, T-cells, and 
inactivate complement and immunoglobulins.  The two main 
proteases, elastase and alkaline protease, facilitate 
necrotizing infections and have the ability to cause 
inactivation of human gamma interferon and tumor necrosis factor 
 10
(Odeh and Quinn, 2000).  Elastase promotes intra-alveolar 
hemorrhage and necrosis by solubilization of elastin-containing 
human lung tissue and degradation of laminin and elastin 
vascular tissue.  Monoclonal antibodies have been developed 
against P. aeruginosa for two different epitopes in which either 
will neutralize proteolytic activity (Kooi et al., 1997). 
 Alkaline protease is the other main protease that is 
secreted by P. aeruginosa (Cryz and Iglewski, 1980).  It is able 
to destroy nonspecific host defenses.  Alkaline protease has 
been associated with corneal infections due to P. aeruginosa.  
Isogenic mutants that possessed no alkaline protease were 
created.  These mutants were still able to establish corneal 
infections, so therefore alkaline protease is not needed in the 
pathogenesis of P. aeruginosa keratitis (Pillar et al., 2000). 
 The hemolysins produced by the bacterium are phospholipase 
C (PLC) and rhamnolipid.  PLC, an alkaline protease, is able to 
degrade the surfactant of the lung.  PLC is able to 
hydrolytically degrade lecithin and phosphatidylcholine.  
Lecithin is an important lipid component of cell membranes which 
could cause cell lysis.  Phosphatidylcholine is a major 
component of lung surfactant (Lema et al., 2000).  Without this 
protective surfactant film, fluid in the lungs could block small 
airways and inhibit proper airflow.  For a cystic fibrosis 
patient, the lungs are left much more susceptible to invasion of 
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infection and bacteria (Lema et al., 2000).  Rhamnolipid, the 
other hemolysin, is also thought to aid PLC in the breakdown of 
lung surfactant by solubilizing the phospholipids (Liu, 1974).  
Rhamnolipid may also play a role in inhibiting the chemotactic 
response of poly-morphonuclear leukocytes (PMNs) during a P. 
aeruginosa infection (Doring et al., 1989). 
 An interesting and unique virulence factor of P. aeruginosa 
is alginate.  Alginate is a linear polymer of β(1→4)-linked D-
mannuronic and C-5 epimer L-guluronic acid that forms a viscous 
gel around the bacteria.  Alginate is a very important factor 
for lung infections.  It aids in the protection of the bacterium 
against phagocytosis.  Once P. aeruginosa has this alginate 
barrier, it is practically impossible for antibiotics or 
surfactants to get across (Fick, 1993).  Studies have shown that 
mucoid (alginate-producing) organisms have a selective advantage 
in their ability to adhere to cilia of the tracheobronchial 
(Baker and Svanborg-Eden, 1989).  This selective advantage is 
shown by the number of casualties of cystic fibrosis patients 
infected with mucoid strains of P. aeruginosa. 
 P. aeruginosa also possesses a flagellum which allows the 
bacterium to be motile.  Motility has a large impact on 
virulence of the pathogen.  The flagellum enables the bacterium 
to be more invasive than the non-flagellum strains (Feldman et 
al., 1998).  It seems that the FlhA component of the flagellum 
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assembly apparatus has a primary role in bacterial 
internalization (Fleiszig et al., 2001).  However, the flagellum 
can provide benefits to the host as well.  Studies have shown 
human antiflagellar monoclonal antibodies can decrease the     
in vitro motility of P. aeruginosa and can reduce its in vivo 
pathogenicity when administered either before or after bacterial 
challenge (Landsperger et al., 1994).  In addition, the presence 
of the flagellum seems to be a key factor in the stimulation of 
nonopsonic phagocytosis of the bacterium by macrophages and 
neutrophils (Mahenthiralingam and Speert, 1995). 
 Along with flagella, P. aeruginosa also produces somatic 
pili, which are also known as fimbrae, and conjugative pili.  
Conjugative pili play an important role in the transfer of 
genetic material between bacteria cells.  Somatic pili are one 
of the most important virulence factors to P. aeruginosa due to 
its function as the initial attachment of the bacterium to the 
epithelial cell of the host.  Pili are able to participate in 
biofilm formation which increases its pathogenicity.  Quorum 
sensing is used by pili to aid in the formation of biofilms.  
Quorum sensing signals are extracellular chemical signals that 
cue cell-density-dependent gene expression.  More extensive 
detail is given below to the structure and function of pili. 
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D. Somatic Pili of P. aeruginosa 
1. Pilus Structure and Classification 
 Pili are characterized as long polar, proteinaceous 
filaments composed of polymers of subunits termed pilin.  They 
stretch from the poles of the bacterial cell in groups of up to 
thirty fibers extending at variable lengths but usually at an 
average of 2.5 µm.  Pili are grouped on the basis of deduced 
amino acid sequences of pilin genes and their assembly 
mechanisms.  P. aeruginosa along with Neisseria gonorrhoeae, 
Neisseria meningitides, Moraxella bovis, and Vibrio cholerae are 
classified as type IV pili.  Type IV pili are also referred to 
as N-methylphenylalanine (NmePhe) pili because NmePhe is the 
first amino acid in the processed pilin subunit (Paranchych, 
1990). Type IV pili consist of several thousand copies of the 
15-18kDa pilin subunit.  The pilins are also composed of a 
highly conserved amino acid sequence homology near the amino 
terminus, a positively charged N-terminus leader peptide of six-
seven amino acids, and a N-methylated phenylalanine at the amino 
terminus of the mature pilin (Mattick et al., 1996). 
 The secondary structure of the pili exhibits a high 
potential for both α-helix and β-sheet formations (figure 2).  
The prediction is that there are β-sheets between residues 2-20 
with two stretches of high α-helix potential at positions 1-9 
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and 16-19.  Further down the pili starting at positions 21, the 
pilin protein subunits are arranged in a helical array with 
approximately five subunits per turn.  The hydrophobic amino 
terminus tail of the pili is kept buried within the center of 
the filament (Forest and Tainer, 1997; Keizer et al., 2001).  
Recent studies based on electrostatic interactions between the 
globular portions of the pilin proteins previous x-ray 
diffraction values have indicated that the coiled N-terminal 
tail of each subunit complements each other.  Once the left-
handed helix is assembled, the outer diameter measures 
approximately 52Å with an internal diameter of 12Å which is 
believed to restrict DNA and/or RNA to pass through with only 
the slight possibility of small organic molecules being able to 
pass through.  If the pili play a substantial role in episomal 
gene transfer and DNA transformation, then it is possible that 
there is a different mechanism for DNA transfer than movement 
through the center of the pilus (Keizer et al., 2001).  The area 
of the pili subunit possessing the N-terminal is highly 
conserved while the remaining two-thirds of the carboxy-terminal 
is rendered highly variable with the exception of the disulfide 
loop domain (Strom and Lory, 1993).  This variability in this 
area is directly correlated with increased antigenic variation, 
aiding P. aeruginosa in escaping host immune defenses 
(Paranchych, 1990).   
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 To understand more on the assembly of the type IV pili, 
researchers felt they needed to focus on providing structural 
information.  In 2000, Hazes et al. studied P. aeruginosa PAK 
pilin by using x-ray and EM analysis to close the gaps on 
structural information.  They identified a novel protein fold 
for the Type IVb pili TcpA and established the extended N-
terminal α helix and central α/β scaffold as conserved features 
of the Type IV pilins (Hazes et al., 2000). 
Figure 2: P. aeruginosa pilin subunit (Hazes et al., 2000) 
                     
 
2. Pilus Synthesis, Assembly, and Regulation 
 There are at least 35 genes involved in the creation of 
Type IV pili (McBride, 2001).  There are three NTP binding 
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proteins required for the assembly and function of pili.  PilU 
and PilT, two NTP binding proteins, are hyperpiliated and 
produce non-motile cells when they are mutated.  These results 
indicate that they are involved in providing energy for 
retraction.  A mutation in PilB, the third NTP binding protein, 
causes nonpiliated cells indicating that PilB provides energy 
essential for assembly (Bardy et al., 2003). 
 The single structural pilin protein is PilA. pilA is 
transcriptionally regulated by alternative sigma factor, σ54, 
which is coded for by the rpoN gene (Ishimoto and Lory, 1989).  
PilA, produced by pilA, is initially made as a prepilin with a 
six amino acid leader peptide which will be cleaved by PilD.  
PilD is a bifunctional enzyme responsible for N-terminal 
processing of the prepilin and for methylation of the N-terminal 
amino acid of the mature protein (Alm and Mattick, 1997).  
Although recent mutational studies have shown that the lack of 
methylation of pilin monomers does not appear to inhibit proper 
pilus functioning, the peptidase function of PilD is essential 
to P. aeruginosa (Pepe and Lory, 1998). 
 PilQ, another essential component for the pilus, is a 77kDa 
protein that forms multimeric, outer membrane pore complexes 
(Bitter et al., 1998).  It allows Type IV pili to cross the 
outer membrane.  Mutations in pilQ yield a non-pilated phenotype 
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with a lack of twitching motility and pilus-specific phage 
resistance (Martin et al., 1995). 
3. Pilus Function 
 The somatic pili of P. aeruginosa exhibit many functions 
for the bacterium.  An important and primary function of pili is 
twitching motility where the bacterium is moving across the 
surface (Bradley, 1980).  Twitching is seen at the agar plate 
interface where the stab inoculation represents the starting 
point for the bacterium.  The bacterium can reach a ~2cm 
diameter after an overnight incubation (Mattick et al., 1996).  
Twitching motility is accomplished by the extending and 
retracting of the pili.  Merz et al. gave strong proof of this 
idea when he and colleagues used laser tweezers to show the 
retracting properties of Type IV pili.  When cells were held 
near the microcolony with these laser tweezers, retractile 
forces pulled the cells toward the microcolony.  They confirmed 
this fact with quantitative experiments.  Immobilized bacteria 
with Type IV pili would bind to latex beads and pull the beads 
from the tweezers.  Overall, the Type IV pili showed that they 
generated substantial force and are able to directly mediate 
cell movement (Merz et al., 2000).  Twitching motility was 
directly observed by fluorescence microscopy in 2001 (Skerker 
and Berg, 2001).  Experiments done by Maier et al. (2002) 
suggest that PilT is an active motor molecule and a single motor 
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complex.  It is able to power the retraction of a single pilus 
with a force in excess of 100pN which would make PilT the 
strongest molecular motor thus far (Maier et al., 2002). 
 Bacteriophage sensitivity also utilizes the retraction and 
extension of the pili.  P. aeruginosa pili operate as receptors 
for many phages, including PO4, PE69, and PP7 (Bradley, 1980).  
Phage infections can occur when the pili attach to the phages 
and retract, therefore, allowing them to come into close 
distance of the bacterium (Bradley, 1972).  Transduction can 
allow new genetic material to be introduced into P. aeruginosa 
by having the phages in close proximity to the bacterium. 
 Another important function of pili is the ability to form 
biofilms.  Biofilms are described as an arrangement of 
microcolonies on biotic or abiotic surfaces (O’Toole and Kolter, 
1998).  P. aeruginosa biofilms are formed when the bacteria come 
into contact with a host surface and attach to it using various 
adhesins, including flagella, Type IV pili, and fimbriae. 
Biofilms are a main cause of death in cystic fibrosis patients 
due to the ability for the bacteria to survive in the lung and 
the secreted toxins and enzymes produced which do extensive 
damage to the lungs.  Recent studies have shown that rhamnolipid 
synthesis by P. aeruginosa is vital to the development and 
architecture of biofilms produced in the lungs of patients 
(Davey et al., 2003). 
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 Quorum sensing is used to assemble biofilms.  The quorum 
sensing signals are extracellular chemical signals that prompt 
cell-density-dependent gene expression.  The biofilms that are 
assembled using quorum sensing are very dense and much harder to 
disrupt (Donabedian, 2002).  Current research shows that quorum 
sensing may be able to serve as a biomarker in screens to 
identify agents that interfere with biofilm development (Singh 
et al., 2000). 
 The pili are used as adhesins for the initial anchoring to 
host tissue and specific receptors.  Pili promote adherence to 
human epithelial cells, however more readily adhere to 
epithelial cells of immunocompromised individuals (Paranchych, 
1990). Specifically, the ligand for the initial anchoring is the 
disulfide loop exposed only at the pilus tip (Irvin et al., 
1989).  This area on the pilus is thought to be the epithelial 
cell binding domain, which is the point of attachment (Farinha 
et al., 1994).  Once the pilus has bound to the receptor on the 
host cell, then the pilus uses its retractable qualities to 
bring it closer to the host cell.  After the bacterium is in 
considerably close range to the host cell, other adhesins are 
allowed to take over and attach the bacterium to the cell which 
will lead to the formation of a microcolony. 
 The pilus can also attach to phagocytes which is a very 
important function when studying the success of vaccines against 
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the bacterium.  Studies have shown that pili do serve as opsonic 
phagocytosis enhancers.  This means that pili can increase the 
uptake of P. aeruginosa by fibronectin-stimulated macrophages 
(Kelly et al., 1989).  So, a vaccine against P. aeruginosa would 
not need to be as concentrated since the body can rid itself of 
a small amount of the bacteria.  Recently, it has been found 
that the rpmA gene, which is used in flagellar movement, is 
required for the efficient ingestion of P. aeruginosa by 
macrophages (Simpson and Speert, 2000).  Flagella have been 
shown to play a role in certain types of infections caused by P. 
aeruginosa which would allow the bacteria to be in closer 
proximity to the macrophages.  This is a very important concept 
when studying a possible vaccine against P. aeruginosa since 
macrophages are able to begin clearing the bacterium from the 
infection site. 
E.  Glycosylation of Pili 
1. Identification of the Glycosylation 
 The study of glycosylation in prokaryotes is relatively new 
to the science world even though glycosylation in eukaryotes is 
very well documented.  Castric and Deal (1994) found that when 
the pilin genes were sequenced from P. aeruginosa, there were 
two distinct groups that became apparent based on the primary 
amino acid structure.  Each strain showed a high conservation of 
sequence near the 5’ end, but greatly differed at the 3’ end of 
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the gene.  The two groups showed differences in that group I had 
a large open reading frame (ORF), later named pilO, downstream 
from pilA and a ribosome binding site while group II only had 
the pilA gene followed by tRNAThr gene (figure 3) (Castric, 
1995). 
Figure 3: Schematic drawing of the Group I and II operons. 
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 The predicted amino acid structure of pilO shows nine 
highly hydrophobic regions.  This structure analysis implies 
that the pilO gene is in a membrane, most likely in the 
cytoplasmic membrane.  To confirm these findings, a pilO 
deficient mutant was constructed by gene replacement technique.  
The mutant was shown to make functional non-glycosylated pili 
(Smedley, 2001).  
2. Glycan Structure 
 P. aeruginosa 1244 pilin glycan is an O-linked 
trisaccharide covalently attached through the β-carbon of a 
serine residue at the C terminus of pilin with a ratio of one 
glycan per pilin subunit (figure 4).  The exact location of the 
glycan on the fiber is unknown.  A characteristic of the Type IV 
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pili is the presence of a disulfide loop (DSL) adjacent to the 
carboxy-terminus.  The DSL is important in pilus-mediated 
adhesin (Lee et al., 1994) and is a dominant B-cell epitope for 
P. aeruginosa 1244 pilin (Comer et al., 2002).  Lee et al. 
(1994) have shown that the DSL is surface-located only at the 
pilus tip.  The proximity of the pilin glycan to the DSL brings 
into question its location on the pilus fiber.  The glycan may 
be evenly distributed over the fiber or concentrated at the 
pilus tip. 
 The determined mass of the glycan is 666.5, which correlates 
with the excess mass of pilin after the value of pilA gene is 
subtracted (Castric et al., 2001) The structure of the glycan 
was found to be identical to the O-antigen repeating unit in LPS 
(see figure 1 for the LPS structure).  This idea suggests that 
pili glycosylation and the addition of O-antigen layer of LPS 
are derived from the same pathway (Castric et al., 2001; 
DiGiandomenico et al., 2002).  Mutants defective in the O-
antigen biosynthetic pathway were unable to glycosylate pilin 
(DiGiandomenico et al., 2002).  It was also found that 
glycosylation process was very non-specific with regards to 
glycan source.  For example, expression of cloned O-antigen 
biosynthesis gene clusters from E.coli resulted in production of 
pili glycosylated with E. coli antigen (DiGiandomenico et al., 
2002).  The glycan along with the pilin DSL region, is shown to 
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be an important B-cell epitope (Comer et al., 2002).  This is of 
particular interest to a potential vaccine because the pilin 
glycan of this bacterium produces antibodies that recognize P. 
aeruginosa 1244 LPS.   
 
Figure 4:  The aminoglycan structure from P. aeruginosa 1244 
pilin. (Castric et al, 2001) This is a product of total 
proteolysis and it is composed of three sugars and a serine. 
 
 
 
3. Function of the Glycan 
 Although studies have shown that the glycan does exist on 
P. aeruginosa 1244 pili, the function has not yet been 
determined.  Possible functions could include blocking the 
binding of complement proteins or masking the epitope for anti-
pilus antibodies.  If it is evenly distributed along the pilus, 
then it could aid in increasing the amount of twitching motility 
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and biofilm formation (Castric et al., 2001).  If the glycan is 
present over the entire surface and possesses a negative charge, 
it may alter the interactions between the pili and the external 
structures causing increased twitching motility and biofilm 
formation.  
 
4. Potential Vaccine Using the Glycan 
Of particular interest to a possible vaccine design, is 
that the glycan stimulates antibodies to recognize LPS from P. 
aeruginosa (Comer et al., 2002).  Therefore, these glycosylated 
pili have the potential to serve as a vaccinating agent in which 
the glycan is the epitope and the bacterial LPS is the immune 
response target.   
 
F. Thesis Goals 
The objectives of this research thesis project are as 
follows: [1] To provide direct microscopic evidence for the 
surface location of the pilus glycan [2] to determine the rabbit 
antibody response by immunization with pure LPS-free pili as 
well as to demonstrate that protective antibodies produced in 
response to the pilin glycan target the pathogen LPS [3] to 
determine an optimal immunization protocol for a long term 
protection study in the murine model and [4] to determine 
whether or not the antibodies in the serum from rabbits that 
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were immunized with pure LPS-free pili could enhance killing of 
the bacteria by the PMNs which would also reveal if phagocytosis 
was due to a pilus-specific or LPS-specific response. 
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II. Materials and Methods 
 
A. Bacterial Strains  
Table 1 comprises a list of all bacterial strains that were 
used in this work.  A brief description of each bacterial strain 
is included. 
Table 1:  Bacterial Strains used in this Work 
Bacterial 
strains 
Description Selectable 
Marker 
Reference 
P. aeruginosa 
1244 
Wild-type, produces 
glycosylated pili and 
flagella,serogroup 
O7strain 
None Castric et al., 
1989 
P. aeruginosa 
1244G7 
PilO-, allelic 
replacement mutant of 
PA1244 
Gmr Smedley, 2001 
P. aeruginosa 
1244.47 
Transposon 
inactivation of pilA 
and pilO genes of PA 
1244 
Hgr Castric 
Unpublished  
P. aeruginosa 
wbpL 
No LPS and 
nonglycosylated pili 
Gmr DiGiandomenico et 
al., 2002 
E. coli HB101 Highly transformable 
strain 
None Sambrook et al., 
1989 
 
 
B. Bacteriological Media and Growth Conditions 
All cultures were grown in LB (Luria Bertani) broth or on 
LB agar plates (pH 7.3) at 37oC for approximately 14 hours, 
unless otherwise noted.  The broth cultures were vigorously 
shaken overnight. 
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C.  Pili Preparation 
Ten milliliters of LB broth was inoculated with the 
specific strain of P. aeruginosa to be tested.  This was 
incubated overnight at 30oC with agitation of 250rpm.  The foil 
covered 70cmx30.5cmx3cm metal culture pans and 500ml CAYE media 
(3.75g of Casamino acids, 0.75g yeast extract, 10g of agar, and 
0.5L deionized water) in 1L flasks were sterilized by 
autoclaving.  The CAYE medium was cooled to 45oC and poured into 
the sterilized metal pans.  When the agar had solidified, 2.5-
3ml of the overnight was added drop wise to the agar surface and 
spread evenly with a sterile hockey stick shaped glass rod over 
the entire surface.  The foil top was replaced and the 
inoculated medium was incubated at 37oC for 14-16 hours.  A 
sterile flat sharp blade with a handle similar to a paint 
scraper was used to loosen the cells from the culture surface 
and a sterilized cotton-tipped applicator was used to transfer 
the cells from the blade to 100ml of 40mM NaPB.  The suspension 
was stirred vigorously for 30 minutes at room temperature.  
After the cells were transferred to a 250ml centrifuge tube, 
they were spun in the centrifuge at 16300 xg in the GSA rotor 
for 30 minutes.  After discarding the pellet, the supernatant 
was measured and the final concentration was adjusted to contain 
3% polyethylene glycol (PEG as described by Silipigni-Fusco, 
1987) and 0.5M NaCl of the final volume while stirring at room 
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temperature (Silipigni-Fusco, 1987).  Once all of the components 
were in solution, the tube was left on ice for two hours.  The 
suspension was spun (GSA rotor) as before and the pellet was 
taken up in the original volume of 100ml of NaPB.  After 
stirring this solution for one hour at room temperature, it was 
spun (GSA rotor) as before and the pellet was discarded.  
PEG/NaCl was added to the supernatant and spun (GSA rotor) as 
before.  The pellet was resuspended with approximately 5ml of 
NaPB and divided among four microfuge tubes.  The solution was 
spun in a microfuge at maximum speed for 5 minutes and the 
pellet was discarded.  In a new microfuge tube, 0.3ml of 15%PEG 
and 2.5M NaCl was added to precipitate the supernatant and then 
stored on ice for 30 minutes.  After spinning in the microfuge, 
the tube was drained completely and the precipitate was stored 
at 4oC.  These pili were used for the electron microscopy work, 
however the pili were further purified for the vaccine studies. 
D.  LPS Extraction 
LPS was extracted from bacterial strains using a method 
described by Hitchcock and Brown (1981).  Two milliliters of 
cells from an overnight broth culture was pelleted, drained, and 
resuspended with 200µl of 1X SDS loading buffer (50mM Tris/HCl pH 
6.8, 100mM DTT, 2% SDS, 0.01% bromophenol blue, 10% glycerol, 
and 0.001% β-mercaptoethanol).  The sample was heated at 95°C for 
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10 minutes, followed by treatment with 25µg of proteinase K for 
one hour at 60°C. 
E.  Transmission Electron Microscopy (TEM) 
Micrographs from the transmission electron microscope were 
produced by preparation of copper grids with P. aeruginosa from 
the overnight culture.  This organism was plated on CAYE plates 
for optimum pili production overnight (14 hours) at 37oC.  The P. 
aeruginosa strains that were used in this experiment were 1244 
and 1244G7.  The bacteria was transferred to 1ml of filter-
sterilized Phosphate Buffer Saline (PBS) (5.3L deionized H2O, 28g 
NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl22H2O, 0.53g MgCl26H2O) by 
a sterile swab and twirled carefully to minimize the amount of 
damage to the pili.  A drop (approximately 100µl) of P. 
aeruginosa and PBS mixture was placed on parafilm and the dull 
side of a formvar-coated copper grid from Electron Microscopy 
Sciences (Fort Washington, PA) was placed on the drop for two 
minutes at room temperature.  The grid was blotted on filter 
paper by touching the shiny side to the paper and allowing the 
liquid to run through the porous grid.  In most cases, the grid 
was fixed at room temperature for 5 minutes with cryofix, which 
consists of 2% paraformaldehyde and 0.01% glutaraldehyde in PBS.  
This material was dispensed in a 20ml syringe with a 0.2µm 
syringe filter.  The grid was then washed with PBS three times 
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for 5 minutes each by placing the grid topside down on a drop of 
PBS at room temperature.  The PBS was dispensed from a 20ml 
syringe with a 0.2µm syringe filter. The method of placing the 
grid topside down on a reactant was continued throughout the 
entire experiment at room temperature.  A follow-up washing with 
BSA solution was used three times at 5 minutes per wash.  The 
BSA solution consists of 0.5% BSA (bovine serum albumin) and 
0.15g of glycine in 100µl of PBS and was dispensed in a 20ml 
syringe with a 0.2µm syringe filter.  The grid was put into 
normal goat serum at a dilution of 1:20 BSA solution for 30 
minutes and then washed with BSA solution three times for 5 
minutes each.  The primary antibody was diluted with 1:1000 in 
PBS and the grid was placed on the primary antibody drop for 60 
minutes.   Another washing with BSA solution was done three 
times at 5 minutes each time.  The grid was now prepared for the 
secondary antibody which was diluted to 1:25 BSA solution.  
Amersham Biosciences (Piscataway, NJ) AuroProbe 5nm gold labeled 
goat anti-mouse IgG was used in this experiment.  The secondary 
antibody was incubated on the grid for 60 minutes.  The grid was 
washed with BSA solution three times for 5 minutes each and PBS 
three times for 5 minutes each.  The entire grid was fixed in 
2.5% glutaraldehyde from Sigma (St. Louis) for 5 minutes.  It 
was dispensed in a 20ml syringe with 0.2µm syringe filter.  The 
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grid was washed in PBS for 5 minutes and then washed in 
sterilized distilled water for 1 minute.  Sigma (St. Louis) 2% 
phosphotungstic acid diluted in deionized water, pH 6 was 
applied to the grid for a second and the grid was allowed to dry 
before putting it in the storage case.  Pictures were taken at 
the Cell Biology and Physiology Department at the University of 
Pittsburgh with the aid of Dr. Donna Stolz.  A JEM 1210 Computer 
Controlled High Contrast 120kV TEM was used.  Pictures taken 
were chosen as a representative field of what was being viewed 
on each grid.  The negatives were developed by standard methods 
of 4 minutes in developer, 1.5 minutes in water rinse, 2.5 
minutes in fixer, 20 minutes in water rinse, and 1 minute in 
Kodak picture protector.  The negatives were printed on the 
Saunders/LPL Super Dichroic 4500II and Rapidoprint DD3700. 
F.  Scanning Electron Microscope (SEM) 
P. aeruginosa was plated on CAYE plates for optimum pili 
production overnight (14 hours) at 37oC.  The P. aeruginosa 
strains used in this experiment were 1244 and 1244G7. The 
bacteria was transferred to 1ml of filter-sterilized PBS (5.3L 
deionized H2O, 28g NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl22H2O, 
0.53g MgCl26H2O) by a sterile swab and twirled carefully to 
minimize the amount of damage to the pili.  Round 12mm cover 
slips were spread with 0.2µl of CellTak obtained from 
Collaborative Biomedical Products (Bedford, MA) and allowed to 
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dry overnight at room temperature.  Excess CellTak was drawn off 
the cover slips with filter paper on the following morning to 
ensure a dry surface.  Approximately 100µl of bacteria cells were 
added to each cover slip and incubated for 10 minutes at room 
temperature.  The cells were fixed with 2% paraformaldehyde from 
Sigma (St. Louis) in PBS for ten minutes.  Excess 
paraformaldehyde was drawn off with filter paper.  The round 
12mm cover slips were placed cell side up into non-sterile 24 
well tissue culture plates.  The cover slips were washed in PBS 
three times for five minutes each and then washed in BSA (PBS 
containing 0.5% BSA and 0.15% glycine) three times for five 
minutes each.  The washing solutions, the antibodies, and the 
glutaraldehyde were added respectively to the wells of the 
tissue plate and allowed to incubate.  Removal of there 
materials from the tissue plate was done using a Pasteur 
pipette.  Normal goat serum diluted 1:20 in the BSA solution was 
used for 45 minutes at room temperature to block the cells.  
Three BSA washings for five minutes each followed.  The primary 
antibody, 11.14, was added to the sample for two hours at room 
temperature followed by six washings of BSA for five minutes 
each.  The secondary antibody, goat anti-mouse conjugated to 
15nm gold particles, was obtained from Amersham Biosciences 
(Piscataway, NJ).  It was diluted to 1:25 in the BSA solution 
and left on the cover slips overnight at 4oC.  Three washings 
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each with the BSA solution and PBS for five minutes followed.  
The cover slips were fixed in 2.5% glutaraldehyde in PBS for one 
hour at room temperature and then washed with PBS three times 
for five minutes each.  A graded series of dehydrations with 
ethanol was completed to remove all of the water in the sample.  
The samples were critically point dried using Emscope 750 
critically point dryer and then over coated with vaporized 
carbon using a Cressington 108Carbon/A carbon coater.  Cells 
were visualized using a JEOL-JEM-6335F field emission gun 
scanning electron microscope at the University of Pittsburgh 
with the aid of Dr. Donna Stolz.  Field emission backscattered 
electron and standard secondary electron digitized images were 
taken in tandem to identify areas of gold labeling on the cell 
surface. 
G.  Vaccine Preparation 
The purification procedure here is a modified version 
(Castric, 1995) of a previously described protocol (Silipigni-
Fusco, 1987).  Strain 1244N3, a mutant that is unable to make 
pilin, could produce glycosylated strain 1244 pilin by carrying 
pPAC46.  pPAC46 is a plasmid that contains strains 1244 pilA and 
pilO genes under the control of a tac promoter.  Glycosylated 
pili produced by hyperexpression of pilA gene of pPAC46 were 
isolated and purified as described above.  This protocol 
produced 10-20mg of pili per liter of culture with traces of 
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LPS.  To rid the sample of LPS contamination, the pili were 
subjected to gel filtration and chromatofocusing in the presence 
of the detergent β-octyl glucoside (βOG).  A 6.12mg glycosylated 
pilin prep was suspended in 700µl of a solution containing 25mM 
Bis-Tris/HCl (pH 7.0), 1% βOG, and 0.02% sodium azide and 
incubated at 24oC for 30 minutes.  After being microcentrifuged 
briefly, the supernatant fluid was applied to a Superose 12 
Column (1.0 by 30cm) that had been equilibrated with the same 
buffer solution.  Two hundred and fifty microliter aliquots were 
taken at a flow rate of 0.5 ml/min.  The major peak was 
determined by the A280.  This material was applied to a Mono P 
anion-exchange column (0.5 by 10cm) that had been equilibrated 
with 25mM Bis-Tris (pH 6.25) containing 0.02% sodium azide.  
Pilin monomer was removed by the addition of a solution 
containing 10% Polybuffer 74 (pH 4.0), 1% βOG, and 0.02% sodium 
azide.  A flow rate of 1.0ml/min and 0.5ml fractions produced a 
single peak which was identified at A280.  It was pooled and 
dialyzed twice against one liter of 5mM Bis-Tris (pH 7.0), which 
allowed reaggregation of the pilin subunits.  To test for the 
presence of LPS, approximately 200µg of reaggregated pilin was 
proteolytically digested by a protocol established by Hitchcock 
and Brown (1983).  A Western blot with LPS-specific monoclonal 
antibody 11.14 was used to analyze the pilin.  The standard was 
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known amount of P. aeruginosa 1244 LPS, either analyzed 
separately or added to aliquots of digested pilin.  LPS, if 
present, was below the level of the lowest standard used meaning 
that any LPS was present at a concentration of less than of 
0.5ng of LPS/µg of pilin. 
H.  Rabbit Immunization 
1. Antibody Production 
 
 All animal work was completed under the rules and 
regulations of the IACUC.  This procedure was carried out by 
Covance Research Products in Denver, PA. The lyopholized pili 
protein (1.15mg/ml) was resuspended in 1ml of saline.  Two NZW 
female rabbits were injected with pure LPS free pili and bled 
every three weeks to determine antibody levels.  The protocol 
can be found in Table 2. 
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 Table 2:  Antibody Production Timeline.  Two rabbits were 
injected with pure LPS-free pili. 
 
Day Procedure 
(1) 
12-10-02 
Prebleed of 5ml of serum 
Injected intradermally in the back at multiple 
sites with a total of 250µg of pili protein 
with adjunct Freund’s Complete Adjuvant (FCA) 
(434µl of pili + 1ml saline + 1ml FCA) 
(21) 
12-31-02 
Boost subcutaneous and intramuscular: total of 
125µg of pili protein with adjunct Freund’s 
Incomplete Adjuvant (FIA) 
(217µl of pili + 1ml saline + 1ml FIA) 
(31) 
1-10-03 
Test Bleed of approximately 5ml of serum 
(42) 
1-21-03 
Boost subcutaneous in the rear flanks: total of 
125µg of pili protein with adjunct FIA 
(217µl of pili + 1ml saline + 1ml FIA) 
(52) 
1-31-03 
Test Bleed of approximately 5ml of serum 
(63) 
2-11-03 Boost subcutaneous in neck: total of 125µg of pili protein with adjunct FIA 
(217µl of pili + 1ml saline + 1ml FIA) 
(73) 
2-21-03 
Production Bleed of approximately 20ml of serum 
(84) 
3-04-03 Boost subcutaneous dorsal: total of 100µg of pili protein with adjunct FIA 
(173µl of pili + 1ml saline + 1ml FIA) 
(94) 
3-14-03 
Production Bleed of approximately 20ml of serum 
(105) 
3-25-03 
Boost subcutaneous in the neck region: total of 
100µg of pili protein with adjunct FIA 
(173µl of pili + 1ml saline + 1ml FIA) 
(115) 
4-04-03 
Production Bleed of approximately 20ml of serum 
(118) 
4-08-03 
Terminal Bleed of approximately 50ml of serum 
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2. Serum Storage 
Four-milliliter aliquots of these sera were placed in glass 
screw top containers and stored at –20oC. 
I.  Mouse Immunization 
1. Immunization Protocol 
 
The protocol employed was approved by the Duquesne University 
Animal Safety Committee, and all procedures required by the 
Committee were followed.  For this study, thirty 6-8 week old 
balb-c female mice (20-25g) were obtained from Hilltop Lab 
(Scottdale, PA).  Each in their own cage, the mice were left 
undisturbed in a non-sterile environment at Duquesne University 
Animal Care Facilities for five days prior to the beginning of 
the experiment.  Introduction of the vaccine into the mice by 
the respiratory route was utilized due to its painless manner 
and its ability to raise mucosal response.  Immunization was 
carried out on anesthetized (0.25cc Ketamine/xylazine) animals.  
Each animal received 10µl of a sterile solution containing 5, 10, 
or 20µg of pure reaggregated P. aeruginosa 1244 pili into each 
nare.  Sham immunized animals only received sterile PBS (5.3L 
deionized H2O, 28g NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl2-2H2O, 
0.53g MgCl2-6H2O), 10µl per nare.  Respiration resulted in the 
aerosolization of the pili with the deposition of the sample in 
the animal’s lungs. 
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  2. Sampling Procedures  
 Three types of samples were taken for determination of 
pilin and LPS-specific antibodies: serum, bronchial lavage, and 
fecal.  Serum samples were taken by cardiac puncture from 
animals anesthetized with a double dose of (0.50cc) 
ketamine/xylazine.  The animal was placed in dorsal recumbency 
and the needle (TB syringe) was inserted to the left of the 
midline at the base of the sternum.  Once blood flowed into the 
hub of the needle, the sample was drawn.  This resulted in 
euthanasia by exsanguination.  After placing the serum sample in 
the refrigerator overnight, serum extraction was completed by 
spinning at 5000 rpm the following morning for 90 seconds.  The 
serum was then drawn off of the whole blood cells and placed in 
a 1.8ml cryotube from Nunc (Denmark) for storage at –20oC. 
 Bronchial lavage (BAL) was carried out on the same animal.  
The trachea was exposed with a scissor cut below the chin, which 
was followed by removal of surrounding tissue with forceps.  The 
exposed trachea was cut half-way through with scissors.  A 1 ml 
syringe of PBS (5.3L deionized H2O, 28g NaCl, 0.7g KCl, 4.0g 
Na2HPO4, 0.35g CaCl22H2O, 0.53g MgCl26H2O) with a 20gauge 1.16IN 
1.1 x 30 mm Angiocatheter (Becton Dickinson; Swedesboro, NJ) at 
the end was slowly ejected into the lungs and drawn back into 
the syringe, therefore producing the lavage sample.  The samples 
were stored in –20oC in 1.8ml cryotubes from Nunc (Denmark). 
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 Fecal pellets produced by each animal were collected.  
These were then weighed to 0.05g and suspended in 300µl of killer 
filler (200ml of 0.1M NaOH supplemented with 10g of casein and 
added to 1.8L of Phosphate Buffer Saline (PBS) [5.3L deionized 
H2O, 28g NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl2-2H2O, 0.53g 
MgCl2-6H2O] containing 10g of bovine serum albumin.  The pH of 
the solution was adjusted to 7.4, followed by the addition of 
0.2g of phenol red and 3.6g of sodium azide [Lynette Young of 
the Walter Reed Army Institute of Research, personal 
communication]).  The sample was centrifuged and the supernatant 
fluid saved.  The samples were stored in –20oC in 1.8ml cryotubes 
from Nunc (Denmark). 
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   3. Schedule of Events 
 Table 3: Overview of Immunization of Mice Protocol.  Day 0 
started at the end of the five-day adjustment period. 
 
Day Treatment 
0 
Immunization of Animals 1-8, 5µg of reaggregated pili 
Immunization of Animals 9-16, 10µg of reaggregated pili 
Immunization of Animals 17-24, 20µg of reaggregated pili 
Sham immunization of Animals 25-30, PBS 
3 Sacrificed Animals 1 & 2, 5µg of reaggregated pili Sacrificed Animals 9 & 10, 10µg of reaggregated pili 
Sacrificed Animals 17 & 18, 20µg of reaggregated pili 
7 
Sacrificed Animals 3 & 4, 5µg of reaggregated pili 
Sacrificed Animals 11 & 12, 10µg of reaggregated pili 
Sacrificed Animals 25 & 26, 20µg of reaggregated pili 
Sacrificed Animals 25 & 26, PBS 
Immunization of Animals 5-8, 5µg of reaggregated pili 
Immunization of Animals 13-16, 10µg of reaggregated pili 
Immunization of Animals 21-24, 20µg of reaggregated pili 
Sham immunization Animals 27-30, PBS 
10 Sacrificed Animals 5 & 6, 5µg of reaggregated pili Sacrificed Animals 13 & 14, 10µg of reaggregated pili 
Sacrificed Animals 21 & 22, 20µg of reaggregated pili 
14 
Sacrificed Animals 7 & 8, 5µg of reaggregated pili 
Sacrificed Animals 15 & 16, 10µg of reaggregated pili 
Sacrificed Animals 23 & 24, 20µg of reaggregated pili 
Sacrificed Animals 27-30, PBS 
 
Antibody capture ELISA test were carried out using 
lipopolysaccharide from P. aeruginosa 1244 as the antigen and 
dilutions of the mouse samples as the primary antibody.  
Antibody types were determined using alkaline phosphatase-
labeled secondary antibodies specific for heavy chain type.  The 
ELISA protocol is outlined below. 
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J.  Immunological Assays 
1. Capture ELISA 
 
A Fisherbrand Clear non-sterile polystyrene 96-well ELISA 
plate from Fisher Scientific (Pittsburgh, PA) was obtained for 
these experiments.  Each of the samples was done in triplicate 
for an average value per sample.  The wells were coated with 50µl 
of 1mg/1ml poly-l-lysine from Sigma (St. Louis) in PBS.  Poly-l-
lysine is a highly positive charged amino acid chain which 
promotes cell adhesion.  The plate was incubated at 30oC for 15 
minutes with constant motion and then washed with PBS (5.3L 
deionized H2O, 28g NaCl, 0.7g KCl, 4.0g Na2HPO4, 0.35g CaCl2-2H2O, 
0.53g MgCl2-6H2O) three times.  A washing with PBS consisted of 
50µl of PBS per well and agitation of the contents by hitting the 
plate with the palm of ones hand.  The PBS was then spilled out 
and the plate was struck onto paper towels to remove excess 
moisture.  The wells were coated with 50µl of 10µg/ml pure LPS 
for 2 hours at 30oC with constant motion and then washed with PBS 
three times.  To block the wells, 400µl of killer filler (10g 
casein, 0.1N NaOH, 10g BSA, 1800ml PBS, adjust pH to 7.4, 0.2g 
Phenol Red, and 3.6g Sodium Azide) was added to each well for 2 
hours at 30oC with constant motion and then washed with PBS three 
times.  Serum to be tested was used as the primary antibody.  
Dilutions of the serum were made ranging from 102 cells/ml to    
 42
5 x 107 cells/ml.  Each well had 50µl of the serum dilutions 
added to it and incubated for 1 hour at 30oC with constant 
motion.  The plate was washed three times with PBS.  Fifty 
microliters of secondary antibody, a phosphatase labeled 
affinity-purified antibody, was added to the wells in a 1:1000 
dilution of killer filler.  The wells were incubated at 30oC for 
90 minutes with constant motion and then washed three times with 
PBS.  The reaction was developed using 50µl of 1mg/ml p-
nitrophenyl phosphate (pNPP) from Fisher Scientific (Fairlawn, 
NJ) which was incubated at 30oC for 30 minutes with constant 
motion.  The reaction was stopped by adding 50µl 0.1M EDTA from 
Fisher Scientific (Fairlawn, NJ) to each well directly on top of 
the pNPP.  The plate was read on an ELISA Bio-Rad Model 3550 
Microplate Reader at a wavelength of 405nm. 
2. Western Immunoblot Analysis 
Western immunoblot analysis was used to visualize cross-
reactivity between pili and LPS O-antigen.  LPS and pili were 
electroblotted on to 0.2-0.45µm nitrocellulose paper (Micron 
Separations Inc.  Westborough, MA) by using the BioRad Mini 
Trans-blot® Electrophoretic Transfer Cell as a constant voltage 
of 100V for 20 minutes in a trans-blot buffer (25mM tris, 192mM 
glycine, 20% methanol, approximate pH 8.3)  
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Upon completion, the nitrocellulose paper was removed and 
blocked overnight at room temperature with constant motion in 
killer filler.  The pieces of nitrocellulose paper were treated 
overnight (approximately 24 hours) with a primary antibody 
solution, production bleed diluted to 1:1000 in killer filler, 
at room temperature with constant motion.  The nitrocellulose 
paper was then washed three times with PBS in 10-minute 
intervals with constant motion.  Once the nitrocellulose paper 
was washed, a phosphatase conjugated secondary goat anti-rabbit 
antibody was diluted to the 10-3 with killer filler.  The 
nitrocellulose paper was then incubated for 90 minutes with 
constant motion.  Two washings with PBS and a washing with 50mM 
tris/HCl pH 8.0 followed.  Reactions were visualized by adding a 
developer solution comprised of 10mg Napthol AS-MX phosphate 
(Sigma Chemical, St. Louis, MO) and 20mg Fast-Red (Sigma 
Chemical, ST. Louis, MO) dissolved in 10ml 50mM tris/HCl pH 8.0 
while gently shaking.  A positive reaction was denoted by the 
development of red bands.  Rinsing the nitrocellulose paper with 
tap water for several seconds terminated the reaction. 
K.  Serum Resistance Assay 
Bacteria strains were grown in 10ml of LB broth for 12 hours 
at 37oC with constant motion.  One hundred microliters was spread 
by the hockey stick method on CAYE plates and incubated at 37oC 
overnight.  After 14 hours of incubation, 5ml of LB broth was 
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added to each plate and gently shaken for 5-10 minutes to loosen 
the bacteria from the plate.  The mixture was transferred to a 
50ml tube using a 10ml pipette to avoid damage to the pili.  In 
a cuvette, the mixture was diluted to a 1:9 ratio with saline to 
measure the absorbance at 650nm.  The concentration of cells was 
calculated by solving the ratio 1.0A/2x109 cells/ml and adjusted 
to 1 x 107 cells/ml in the sample.  The reaction 1 contained 70µl 
of bacterial cells, 0µl of mouse serum, and 30µl of saline.  
Reaction 2 contained 70µl of bacterial cells, 30µl of mouse 
serum, and 0µl of saline.   
Each reaction tube was incubated at 37oC.  At time 30, 60, and 
120 minutes, 20µl of each reaction mixture was removed and 
diluted in 980µl saline (10^5 cells/ml).  Subsequent dilutions 
were made to the concentration 104 cells/ml and 103 cells/ml.  
Reaction 1 was also completed at time 0.  Each LB plate was 
inoculated with 100µl of each dilution from each reaction mixture 
and spread evenly using the hockey stick method.  The plates 
were incubated overnight at 37oC and the colonies were counted 
and recorded the following day. 
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L.  Opsonization Assay 
P. aeruginosa strains to be tested were grown in 5ml LB broth 
for 14 hours at 37oC at 250rpm.  A secondary culture was started 
by adding 100µl of the overnight culture to 5 ml of LB broth and 
incubated in 37oC with constant motion.  Blood samples (from 
myself) were drawn from the arm by the nursing staff at Duquesne 
University.  The sample was placed in a heparinized tube on ice 
to prevent clotting.  In a plastic tube, 2ml of heparinized 
blood and 2ml of sterilized saline (8.5g NaCl/L) were added and 
mixed by drawing the fluid in and out of a 10ml pipette.  The 
blood/saline mixture was placed in a 15ml sterilized centrifuge 
tube on top of 3ml of sterile Ficol-Paque Plus from Amersham 
Biosciences (Piscataway, NJ) using caution to keep the two 
solutions separate.  The mixture was centrifuged at 1600rpm for 
30-40 minutes at 18-20oC.  The upper layer was drawn off using a 
sterile Pasteur pipette, leaving the lymphocyte layer 
undisturbed at the interface and the red blood cells at the 
bottom of the centrifuge tube.  Using a clean sterile Pasteur 
pipette, the lymphocyte layer is transferred to a clean sterile 
15ml centrifuge tube.  The cells are re-suspended in 6mL of 
saline by carefully drawing them in and out of a Pasteur 
pipette.  The solution was centrifuged again at 2300 rpm for 10 
minutes at 18-20oC.  After removing the supernatant, the 
lymphocytes were re-suspended in 6ml of saline.  The 
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centrifugation of the solution was repeated at 2300 rpm for 10 
minutes at 18-20oC.  The washing was repeated and the supernatant 
was removed.  The lymphocytes were re-suspended in 200µl of 
saline.  The viable cells, which appeared larger and had a 
whitish glow whereas the dead cells were withered and brown in 
color, were counted using a hemocytometer under a phase contrast 
scope at 400 magnification.  Cells were counted per block (area 
= 4.2 x 105 mm3) and the mean was determined after approximately 
600 cells were counted.   
The absorbance at 650nm for the secondary bacterial culture 
was found and the concentration of cells/ml was determined by 
using the ratio of the known value of 1.0A/2x109 cells/ml.  The 
concentration was then adjusted to 3 x 107 cells/ml.  The 
bacterial cells were centrifuged and the supernatant was 
removed.  The cells were then re-suspended in 1ml of saline to 
eliminate contamination from the LB broth which could render the 
results invalid.   
Control and test solutions were prepared.  The control mixture 
consisted of 100µl of bacterial cells and 300µl of saline.  The 
test mixture contained 100µl of bacterial cells, 100µl human 
complement, 100µl white blood cells, and 100µl rabbit serum.  
These solutions were incubated at 37oC.  Aliquots were removed at 
0, 30, and 60 minutes, diluted with sterile saline, and plated 
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out.  The LB plates were incubated overnight at 37oC.  Cell 
colonies were counted and recorded the following morning. 
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III. Results 
A. Electron Microscopy Results on Glycosylated and 
Nonglycosylated P. aeruginosa 
1.Transmission Electron Microscopy 
 
a. Whole Cells 
 
Previous work by Castric (1995) has shown that pili from this 
organism are glycosylated but the specific location of the 
glycan on the fiber remains unknown.  A characteristic of the 
pilin of P. aeruginosa is the presence of a disulfide loop (DSL) 
adjacent to the carboxy-terminus which is important in pilus-
mediated adhesin (Lee et al., 1994).  Lee et al. (1994) have 
shown that the DSL is surface-located only at the pilus tip.  
The proximity of the pilin glycan to the DSL brings into 
question its location on the pilus fiber.   The goal of this 
study is to determine whether it is evenly distributed over the 
surface of the fiber or concentrated at the pilus tip.  In order 
to accomplish this, whole cells and isolated pili were analyzed 
using transmission electron microscopy (TEM) and scanning 
electron microscopy (SEM).  The pilin saccharides were located 
using a glycan-specific monoclonal antibody and visualized using 
a gold-labeled secondary antibody.   
Typical TEM micrographs of whole cell P. aeruginosa 1244 and 
1244G7, a mutant that lacks a pilO gene and produces 
nonglycosylated pilin (Smedley, 2001), can be found in Figure 5 
and Figure 6, respectively.  There is no observable difference 
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in length, thickness, or amount of pili observed between 
glycosylated and nonglycosylated strains.  P. aeruginosa 1244 
and 1244G7 cells were treated with the monoclonal glycan 
specific antibody, 11.14, and a secondary antibody conjugated 
with gold particles in order to determine the glycan location.  
Gold labeling can be seen on the pili and on the cell surface of 
1244 (Figure 7). No gold particles were seen on the flagellum 
which suggests the observed reaction is not due to LPS 
contamination.  There were no gold particles found on the pili 
of nonglycosylated P. aeruginosa 1244G7.  But like strain 1244, 
there was gold-labeling found associated with LPS on the cell 
surface (Figure 8).  Of major importance was the finding that 
gold labeling was seen along the entire 1244 fiber.  This 
suggests that glycan is not located only at the tip of the 
fiber, but over the entire pilus surface.   
 As a control to ensure that this procedure was working, P. 
aeruginosa 1244 and 1244G7 cells were treated with secondary 
antibodies in the absence of the glycan-specific monoclonal. 
There were no gold particles found on either strains 1244 or 
1244G7 (Figure 9 and 10, respectively).  Therefore, the glycan 
specific monoclonal antibody is needed for the reaction to be 
seen. 
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b. Isolated Pili 
 To ensure that the whole cell results were not an artifact, 
P. aeruginosa 1244 and 1244G7 isolated pili were also observed 
with no antibody probes and with the monoclonal glycan-specific 
antibody.  Typical TEM pictures of isolated pili from P. 
aeruginosa strains 1244 and 1244G7 can be found in Figure 11 and 
12, respectively.  There is no observable difference in length, 
thickness, or amount of pili observed between glycosylated and 
nonglycosylated strains.  P. aeruginosa 1244 and 1244G7 isolated 
pili were treated with the monoclonal glycan specific antibody, 
11.14, and the secondary antibody conjugated with gold particles 
in order to determine the glycan location. It was found that P. 
aeruginosa 1244 isolated pili did have gold particles along the 
pilus (Figure 13).  P. aeruginosa 1244G7 did not have gold 
particles on the pilus.  However, there was LPS contamination 
located not on the pilus fiber but with debris surrounding the 
pilus which caused gold particles to be seen in areas of LPS 
clumping (Figure 14).  After additional purification cycles (as 
described in the materials and methods section) of the 1244G7 
pili, there was no debris found so no gold particles were found 
(Figure 15).  This confirms the whole cell results that the 
glycan is surface located.  It is found on the entire surface of 
the pili and is not just concentrated at the tip of the fiber. 
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2. Scanning Electron Microscopy 
 In order to confirm the TEM results, P. aeruginosa 1244 and 
1244G7 cells were subjected to the procedure described above and 
analyzed using SEM.  Controls are shown of P. aeruginosa 1244 
and 1244G7 cells treated with the secondary antibody in the 
absence of the monoclonal antibody in Figure 16 and 17, 
respectively.  Gold particles were not seen on either of the 
backscatter electron images suggesting that the primary 
monoclonal antibody is needed for a reaction to be seen.  There 
was no observable difference in appearance of the cells, pili, 
or flagellum between the strains observed in the controls.  
Next, the strains were treated with the monoclonal glycan 
specific antibody, 11.14, and the secondary antibody conjugated 
with gold particles.  In Figure 18, gold particles can be seen 
on the P. aerguinosa 1244 pili shown in the secondary 
backscatter electron images, therefore demonstrating that the 
glycan is found over the entire surface of the pili and not just 
at the tip of the fiber.  Gold labeling was also seen on the 
cell surface of P. aeruginosa 1244. However, no gold particles 
were seen on the P. aeruginosa 1244G7 pili shown in the 
secondary backscatter electron image (Figure 19).  Gold labeling 
was observed on the cell surface of P. aeruginosa 1244G7.  This 
indicates that the results seen in Figure 18 were not due to LPS 
contamination.  The SEM results confirmed the findings that the 
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glycan is evenly distributed over the pilus fiber as found by 
the TEM results.  Therefore, the glycan is only associated with 
1244 glycosylated pili which is visualized using the secondary 
backscatter electron images.  The cell surface of both strains 
was strongly illuminated in the secondary backscatter electron 
images by the reaction with the monoclonal antibody suggesting 
that it is associated with the O-antigen of LPS found on the 
cell surface. 
 The SEM results confirmed the finding of the TEM that the 
glycan is surface-located and evenly distributed over the pilus 
structure.  The glycan was only seen in the glycosylated 1244 
strain of P. aeruginosa.     
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Figure 5:  P. aeruginosa 1244 whole cell, no primary or 
secondary antibody. The negatively stained bacterium was 
observed under 50K magnification on the Transmission Electron 
Microscope. 
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Figure 6: P. aeruginosa 1244G7 whole cell, no primary or 
secondary antibody.  The negatively stained bacterium was 
observed under 50K magnification on the Transmission Electron 
Microscope. 
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Figure 7: P. aeruginosa 1244 whole cell with the 11.14 primary 
antibody and secondary antibody conjugated with gold particles.  
The negatively stained bacterium was observed under 50K 
magnification on the TEM. 
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Figure 8:  P. aeruginosa 1244G7 whole cell with the 11.14 
primary antibody and secondary antibody conjugated with gold 
particles. The negatively stained bacterium was observed under 
50K magnification on the TEM. 
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Figure 9:  P. aeruginosa 1244 whole cell, secondary antibody 
conjugated with gold particles.  The negatively stained 
bacterium was observed under 50K magnification on the TEM. 
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Figure 10:  P. aeruginosa 1244G7 whole cell, secondary antibody 
conjugated with gold particles.  The negatively stained 
bacterium was observed under 50K magnification on the TEM. 
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Figure 11: P. aeruginosa 1244 isolated pili, no primary antibody 
and secondary antibody.  The negatively stained bacterium was 
observed under 25K magnification on the TEM. 
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Figure 12: P. aeruginosa 1244G7 isolated pili, no primary 
antibody and secondary antibody.  The negatively stained 
bacterium was observed under 25K magnification on the TEM. 
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Figure 13: P. aeruginosa 1244 isolated pili, 11.14 primary 
antibody and secondary antibody conjugated with gold particles.  
The negatively stained bacterium was observed under 50K 
magnification on the TEM. 
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Figure 14: P. aeruginosa 1244G7 isolated pili, 11.14 primary 
antibody and secondary antibody conjugated with gold particles.  
The negatively stained bacterium was observed under 50K 
magnification on the TEM. 
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Figure 15: P. aeruginosa 1244G7 isolated pili, 11.14 primary 
antibody and secondary antibody conjugated with gold particles.  
To rid the sample of LPS contamination seen in figure 11, this 
sample was further purified.  The negatively stained bacterium 
was observed under 50K magnification on the TEM. 
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Figure 16: P. aeruginosa 1244, secondary antibody conjugated 
with gold particles.  The bacterium was viewed at 43K on the 
scanning electron microscope.  Panel A is the standard electron 
digitized image and panel B is the field emission secondary 
backscattered electron digitized image. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17:  P. aeruginosa 1244G7, secondary antibody conjugated 
with gold particles.  The bacterium was viewed at 43K on the 
scanning electron microscope.  Panel A is the standard electron 
digitized image and panel B is the field emission secondary 
backscattered electron digitized image. 
A B
A B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65
Figure 18: P. aeruginosa 1244, 11.14 primary antibody and 
secondary antibody conjugated with gold particles.  The 
bacterium was viewed at 43K on the scanning electron microscope.  
Panel A is the standard electron digitized image and panel B is 
the field emission backscattered electron digitized image. 
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Figure 19: P. aeruginosa 1244G7, 11.14 primary antibody and 
secondary antibody conjugated with gold particles.  The 
bacterium was viewed at 43K on the scanning electron microscope.  
Panel A is the standard electron digitized image and panel B is 
the field emission backscattered electron digitized image. 
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 B. Immunogenicity of pilin glycan 
1. Rabbit Studies 
 
 This set of experiments was designed to determine the 
rabbit antibody response by immunization with pure LPS-free 
pili.  Analysis of the antibodies produced would: 1) determine 
the extent to which these pili stimulate the production of anti-
LPS antibodies, 2) produce a reagent that could be used for 
opsonization assays, and 3) determine whether IgG or IgM is the 
dominant anti-LPS antibody produced.  
Each bleed was analyzed using the protocol described in 
Materials and Methods. LPS was used as the antigen and anti-IgG 
antibodies were used to detect the probe using an ELISA assay.  
A graph in Figure 20 describes an overview of the progressive 
increase in antibody production over the course of the 
experiment.  The serum produced a high titer of IgG antibodies 
at a dilution of 1 x 10-6 as shown in table 4.  The negative log 
of serum dilutions were derived by using a constant endpoint of 
0.100 (A410 for 30 minutes incubation at 30°C). This endpoint 
provides a point where the three groups can be compared with one 
another.  
A Western blot using the DQ4 rabbit production bleed as the 
primary antibody was completed with pure pilin or pure LPS as a 
target (Figure 21).  There was a strong response seen in the 
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lanes with pilin and in the lanes with LPS.  Therefore, the 
Western blot illustrated two responses, a pili response and a 
typical “ladder” response seen with LPS, which were recognized 
by the rabbit antibodies.  This demonstrates that the rabbit 
produces antibodies that recognize LPS when were injected with 
pure LPS-free pili. 
To determine whether there was a response against IgM 
antibodies, an ELISA assay was completed with the terminating 
bleed as the primary antibody and anti-IgM specific as the 
secondary antibody.  A low titer of IgM antibodies were seen in 
both rabbits (Figure 22).  There was a 4-log difference between 
the IgM and IgG antibodies.  The IgM antibodies at the 0.05 
endpoint were at a serum dilution of 1 x 10-2 while the IgG 
antibodies had a serum dilution of 1 x 10-6.  Therefore, there is 
an observable difference between the response of the level of 
IgG and the IgM antibodies. 
 These assays showed that rabbits injected with pure LPS-
free pili produced a strong titer of IgG antibodies directed 
against LPS.  There was also a low titer of IgM antibodies 
produced in the serum.   The rabbit serum were used in following 
experiments to determine if there was opsonization. 
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Figure 20: IgG Antibody Response against LPS from Rabbit DQ3 and 
DQ4 summarized by a line graph.  Secondary IgG antibody in the 
ELISA assay was used to determine specific values of the 
response.  The amount of antibodies present continues to 
increase with time.  The highest titer is found from the 
terminating bleed completed on 4-11-03. 
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Table 4: Summary of IgG Antibody Response against LPS to pure 
LPS-free pili in rabbits.  Values were obtained from the ELISA 
assay.  All numbers were generated from a constant endpoint 
which provides a point where the three groups can be compared 
with one another. 
Serum Used to 
Determine 
Antibody Level 
Days Past 
Initial 
Immunization 
DQ3 Rabbit 
Antibody 
Levels 
(-log of serum 
dilution) 
DQ4 Rabbit 
Antibody 
Levels 
(-log of serum 
dilution) 
Pre Bleed 
12-10-02  
1 0.00 0.00 
Production 
Bleed 
2-21-03  
73 4.30 5.00 
Terminating 
Bleed 
4-11-03  
118 5.30 6.00 
 
Figure 21: Western Blot Analysis of DQ4 Rabbit Sera showing 
anti-pilin and anti-LPS response.  Lane 1 contained 5µl of 
standard molecular marker.  Lane 2, 3, and 4 had .25µg, .5µg, 
and 1.0µg of pilin, respectively. Lane 5, 6, and 9 had nothing 
added.  Lane 7 and 8 have 30µl of LPS (7.5µg).  The 
nitrocellulose paper was incubated with the rabbit production 
bleed sera diluted to 1:1000 in killer filler (Materials and 
Methods). 
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Figure 22: IgM Antibody Response against LPS using the rabbits’ 
termination bleed (118 days past initial immunization) 
summarized by a line graph.  Secondary IgM antibody was used to 
determine specific values of the response.  The IgM antibody is 
strong in an initial response, however drops off quickly as 
other immune responses begin to take action. 
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2. Mouse Studies 
 
In order to carry out a comprehensive protection studies 
employing a pilus vaccine and using the mouse respiratory model, 
it will be necessary to determine an optimal immunization 
protocol.  A group of thirty 6-8 week old balb-c female mice 
(20-25g) were obtained and immunized by the intranasal route 
with 5µg, 10µg, or 20µg of pure LPS-free reaggregated pili or PBS 
as a control (table 5).  A fecal, serum, and BAL (bronchial 
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lavage) sample was collected from each mouse.  The fecal samples 
would contain antibodies that would be present in the 
gastrointestinal tract.  Because the antigen was processed via 
the mucosal route, high antibody levels should be present in the 
small intestine.  The serum samples were tested to determine the 
titer of antibodies produced by the mouse that were present in 
the blood.  The BAL samples were tested to reveal how many 
antibodies were produced in the lungs, which was the site of 
immunization.  The samples were used in an ELISA assay with LPS 
as the antigen to determine the concentration of antibodies 
present. 
The results show that IgM are the type of antibodies being 
produced in the serum of the mice throughout the duration of the 
experiment (table 6-9).  The antibody levels from the mice that 
were immunized with reaggregated pili were similar levels to the 
antibody levels of the sham-immunized mice.  The BAL and fecal 
samples produced no response in this experiment. IgA antibodies 
were not present in any of the samples.  However, there was a 
slight increase in IgG antibodies in the 20µg reaggregated pili-
injected mice shown in table 8.  The sham-immunized mice also 
produced a low response of IgG antibodies as shown in table 9.   
Overall, there was an antibody response being produced in 
this experiment, however the antibody levels produced by the 
reaggregated-immunized mice and the sham-immunized mice were 
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similar.  These levels from the mice did not correlate with the 
rabbit immunogenicity results.  The rabbits produced a high 
titer of IgG antibodies against pure LPS-free pili whereas the 
mice did not produce a similar response against the same 
antigen. 
 
Table 5: Overview of Immunization of Mice Protocol.  Day 0 
started at the end of the five-day adjustment period. 
 
Day Treatment 
0 
Immunization of Animals 1-8, 5µg of reaggregated pili 
Immunization of Animals 9-16, 10µg of reaggregated pili 
Immunization of Animals 17-24, 20µg of reaggregated pili 
Sham immunization of Animals 25-30, PBS 
3 Sacrificed Animals 1 & 2, 5µg of reaggregated pili Sacrificed Animals 9 & 10, 10µg of reaggregated pili 
Sacrificed Animals 17 & 18, 20µg of reaggregated pili 
7 
Sacrificed Animals 3 & 4, 5µg of reaggregated pili 
Sacrificed Animals 11 & 12, 10µg of reaggregated pili 
Sacrificed Animals 25 & 26, 20µg of reaggregated pili 
Sacrificed Animals 25 & 26, PBS 
Immunization of Animals 5-8, 5µg of reaggregated pili 
Immunization of Animals 13-16, 10µg of reaggregated pili 
Immunization of Animals 21-24, 20µg of reaggregated pili 
Sham immunization Animals 27-30, PBS 
10 Sacrificed Animals 5 & 6, 5µg of reaggregated pili Sacrificed Animals 13 & 14, 10µg of reaggregated pili 
Sacrificed Animals 21 & 22, 20µg of reaggregated pili 
14 
Sacrificed Animals 7 & 8, 5µg of reaggregated pili 
Sacrificed Animals 15 & 16, 10µg of reaggregated pili 
Sacrificed Animals 23 & 24, 20µg of reaggregated pili 
Sacrificed Animals 27-30, PBS 
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Table 6: Comparison of 5µg pure LPS-free reaggregated pili-
injected mice at the endpoint on titration curves against LPS.  
The values represent the –log of the antibody dilution.  The 
numbers in parenthesis stand for (the number of times the mice 
were injected, the number of days the mice were terminated after 
day 1).  
 
 FECAL BAL SERUM 
 IgG IgA IgM IgG IgA IgM IgG IgA IgM 
Group 1 (1,3) 0 0 0 0 0 0 0 0 2.11 
Group 2 (1,7) 0 0 0 0 0 0 0 0 1.42 
Group 3 (2,10) 0 0 0 0 0 0 0 0 1.88 
Group 4 (2,14) 0 0 0 0 0 0 0 0 1.19 
 
 
Table 7: Comparison of 10µg pure LPS-free reaggregated pili-
injected mice at the endpoint on titration curves against LPS.  
The values represent the –log of the antibody dilution.  The 
numbers in parenthesis stand for (the number of times the mice 
were injected, the number of days the mice were terminated after 
day 1).  
 
 FECAL BAL SERUM 
 IgG IgA IgM IgG IgA IgM IgG IgA IgM 
Group 1 (1,3) 0 0 0 0 0 0 0 0 1.65 
Group 2 (1,7) 0 0 0 0 0 0 0 0 1.74 
Group 3 (2,10) 0 0 0 0 0 0 0 0 1.48 
Group 4 (2,14) 0 0 0 0 0 0 0 0 1.38 
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Table 8: Comparison of 20µg pure LPS-free reaggregated pili-
injected mice at the endpoint on titration curves against LPS.  
The values represent the –log of the antibody dilution.  The 
numbers in parenthesis stand for (the number of times the mouse 
was injected, the number of days the mouse was terminated after 
day 1).  
 
 FECAL BAL SERUM 
 IgG IgA IgM IgG IgA IgM IgG IgA IgM 
Group 1 (1,3) 0.242 0.392 0 0 0 0 0.312 0 1.51 
Group 2 (1,7) 0 0 0 0 0 0 0.670 0 1.78 
Group 3 (2,10) 0 0 0 0 0 0 1.43 0 3.07 
Group 4 (2,14) 0 0 0 0 0 0 0 0 1.55 
 
Table 9: Comparison of PBS-injected mice at the endpoint on 
titration curves against LPS.  The values represent the –log of 
the antibody dilution.  The numbers in parenthesis stand for 
(the number of times the mouse was injected, the number of days 
the mouse was terminated after day 1).  
 
 FECAL BAL SERUM 
 IgG IgA IgM IgG IgA IgM IgG IgA IgM 
Group 1 (1,7) 0 0 0 0 0 0 0 0 1.85 
Group 2 (2,14) 0 0 0.134 0 0 0 0.380 0 1.62 
 
C. Protection Studies 
 
1. Determination of Serum Sensitivity of  
P. aeruginosa strains 
 Prior to the opsonization assays, P. aeruginosa strains 
1244 and 1244.47 were tested for mouse serum sensitivity.  The 
serum is used in the opsonization assay as a source of 
antibodies, therefore if there was serum sensitivity then the 
opsonization results would be invalid.  Strain 1244 was used in 
this experiment because it expressed pili whereas 1244.47 did 
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not produce any pili, therefore showing whether or not serum 
resistance was due to the presence of pili.  Reaction 1 
consisted of 70µl of bacterial cells at a concentration of 1x107 
cells/ml and 30µl of saline whereas reaction 2 consisted of 70µl 
of bacterial cells at a concentration of 1x107 and 30µl of 
undiluted mouse serum from Sigma (St. Louis).  The two reactions 
were incubated at 37°C, diluted, and plated on LB plates over 
timed intervals.  The viable cells were counted the following 
morning.  Neither strain was serum sensitive as shown in Figure 
23, thus a factor(s) other than the presence of pili mediates 
serum resistance.  Because these strains were not killed by the 
mouse serum, opsonization assays can now be conducted using this 
serum and these strains. 
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Figure 23: Serum resistance assay results derived from 1244 and 
1244.47.  Reaction 1 contains 70µl of bacterial cells at a 
concentration of 1x107 and 30µl of saline.  Reaction 2 contains 
70µl of bacterial cells at a concentration of 1x107 and 30µl of 
undiluted mouse serum.  The two reactions were incubated at 37°C, 
diluted, and plated on LB plates over timed intervals. 
Measurements are made in the number of viable colonies. 
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2. Opsonization Assay 
 Opsonization is the process whereby antibodies attach to an 
invading bacterium making it more vulnerable to phagocytosis.  
Polymorphonuclear leukocytes (PMNs) are a type of white blood 
cell, abundant in mammalian blood, and engulf bacteria via 
phagocytosis.  The goal of the opsonization assays was to 
determine whether or not the antibodies in the serum from 
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rabbits that were immunized with pure LPS-free pili could 
enhance the killing of the bacteria by the PMNs.  In addition, 
these assays would reveal if phagocytosis was due to a pilus-
specific or LPS-specific response by the rabbit antibodies.    
Various combinations of PMNs from human volunteers, rabbit 
serum, saline, human complement, and bacterial cells were 
incubated at 37°C, diluted, and plated on LB plates over timed 
intervals.  As a control to ensure that the assay was 
functioning properly, strains E. coli HB101, which lacks an O-
antigen, and P. aeruginosa 1244wbpL, which has no O-antigen but 
does possess non-glycosylated pili, were used.  E. coli HB101 
and P. aeruginosa 1244wbpL should be susceptible to PMN killing 
(Boyer H.W., 1969), even in the absence of serum due to the 
absence of an O-antigen.  Furthermore, opsonization should occur 
in tests using P. aeruginosa 1244 wbpL because of the presence 
of anti-pilus antibodies in the serum.  The results showed that 
killing of the bacteria was observed in the assays using strains 
E. coli HB101 and P. aeruginosa 1244wbpL which conveys that the 
assay is functioning properly (Figure 24). 
Since the control strains showed that the assay was working 
properly, P. aeruginosa 1244 and 1244.47 were tested for 
opsonization using the rabbit antibodies and PMNs as previously 
described.  Strains 1244, which possesses glycosylated pili, and 
1244.47, which does not produce pili, were used to show whether 
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or not opsonization was pili-mediated.  However, if both strains 
decreased in the number of viable cells, then the results would 
suggest an LPS-mediated response because these strains share the 
same O-antigen.  Results showed no decrease of viable cells of 
either strain (Figure 25). This assay was repeated utilizing 
various types of complement such as baby rabbit and human, all 
with the same negative results.  
Overall, the results suggest that P. aeruginosa 1244 and 
1244.47 were resistant to phagocytosis by PMNs since killing was 
not observed. Therefore, the rabbit serum was unable to elicit 
opsonization in these strains due to the high resistance to 
phagocytosis exhibited by P. aeruginosa 1244 and 1244.47. 
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Figure 24: Opsonization assay results derived from E. coli HB101 
and P. aeruginosa 1244wbpL. Control run consisted of 100µl of 
bacterial cells and 300µl of saline. The test run consisted of 
100µl bacterial cells, 100µl white blood cells (PMNs), 100µl 
human complement, and 100µl rabbit serum.  Both the control and 
the test run were incubated at 37°C, diluted, and plated on LB 
plates over timed intervals.  Measurements were then made in the 
number of colonies. 
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Figure 25: Opsonization assay results derived from strains 1244 
and 1244.47. Control run consisted of 100µl of bacterial cells 
and 300µl of saline. The test run consisted of 100µl bacterial 
cells, 100µl white blood cells (PMNs), 100µl human complement, 
and 100µl rabbit serum.  Both the control and the test run were 
incubated at 37°C, diluted, and plated on LB plates over timed 
intervals.  Measurements are made in the number of colonies. 
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IV. Discussion 
 
A. Electron Microscopy  
The pili of P. aeruginosa are made up of a single type of 
pilin subunit which has the physical and chemical 
characteristics associated with those of the type IV pili (Strom 
and Lory, 1993).  One of these characteristics is the N-
methylation of the amino-terminal residue, phenylalanine.  In 
addition to this modification, the carboxy-terminal residue, a 
serine, of P. aeruginosa 1244 pilin is glycosylated (Comer et 
al., 2002).  This glycan is a trisaccharide that is identical 
with the O-antigen repeating unit of the lipopolysaccharide 
produced by this organism (Castric et al., 2001).  Pilin 
glycosylation by this organism requires the presence of pilO, a 
gene that is a component of the operon containing pilA, the 
pilin structural gene (Castric, 1995). 
 Another characteristic of the Type IV pili is the presence 
of a disulfide loop (DSL) adjacent to the carboxy-terminus.  The 
DSL is important in pilus-mediated adhesin (Lee et al., 1994) 
and is a dominant B-cell epitope (Comer et al., 2002).  Lee et 
al. (1994) have shown that the DSL is surface-located only at 
the pilus tip.  The proximity of the pilin glycan to the DSL 
brings in to question its location on the pilus fiber.  The 
present study provides evidence by using monoclonal glycan-
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specific antibodies that the glycan is located at the pilus 
surface.  Further, the results show that this structure is 
distributed evenly over the pilus. 
 These findings suggest that the hydrophilic nature of the 
glycan can be expected to have a significant effect on the 
physical and chemical properties of the pilus.  The pilus is 
normally hydrophobic (Castric, unpublished), however, the glycan 
on the surface of this structure makes it less hydrophobic and 
more hydrophilic.  The glycan is negatively charged due to the 
ionic character of Pseudaminic acid found at the glycan 
terminus.  Hydrogen bonding of the sugar residues increases 
hydrophilicity. 
The presence of the pilin glycan likely influences pilus 
function.  Since LPS and the glycan have identical structure, 
this may play a direct role in adhesion for the bacteria because 
LPS is a known adhesin.  Therefore, the glycan may be an adhesin 
as well where is could possibly aid or modify binding to host 
epithelial cells in various parts of the body.   
Studies done by Smedley (2001) have shown that the pilus 
glycan has a direct effect on twitching motility.  He found that 
the P. aeruginosa 1244 mutant, which was unable to glycosylate 
pilin, was able to synthesize functional pili.  Its average 
twitching was ~26% less than the wild type.  This could be due 
to the absence of the glycan on the pilus surface.  The negative 
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charge and hydrophilicity produced by the glycan may alter the 
interactions between the pili and other structures external to 
the cell.  To see if this is the case, experiments measuring the 
interaction of purified glycosylated and non-glycosylated pili 
to cells will need to be carried out.   
 The glycan may also aid in epitope masking of the pilus-
binding site by sterically blocking antibodies from binding.  By 
blocking the binding site, this would hinder the ability for the 
antibodies from the immune system to bind to the bacterial 
cells.  It would be advantageous for the bacterium to defend 
itself in this way since the immune system upon initial 
infection responds by producing antibodies for neutralization of 
the bacterial cells.  This would increase the success of the 
bacteria to be able to initiate an infection. 
The results found in this study show that a vaccine could 
be effective against pili. Since the glycan is located over the 
entire surface of the pilus, it is highly concentrated with many 
binding sites available.  This allows cross-linking to occur 
which will result in inhibition or decreased twitching (Castric 
et al., 2001) by the pili.  Since the twitching motility has 
been linked to the bacterium’s pathogenicity, then inhibiting 
twitching will cause it to be avirulent.  This could be an 
important point in making an effective vaccine.  Also, the pili 
have identical structure to the O-antigen repeating unit of LPS 
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and LPS cannot be injected into humans due to endotoxin A, 
therefore the glycosylated pili would be a good vaccine 
candidate against all strains of Pseudomonas. It would not 
matter whether they had pili or not since they all have LPS to 
respond against. 
 Overall, the results from the TEM illustrate that P. 
aeruginosa 1244 pili are glycosylated in which the glycan is 
located over the entire surface of the fiber shown by the gold 
particles. Whereas 1244G7 is not glycosylated shown by the lack 
of gold particles on the pili.  Gold particles were seen on the 
cell surface of 1244 and 1244G7 which suggests that the anti-
glycan antibodies recognize the LPS present.   
The SEM results also suggested that the glycan location was 
found on the entire surface of the pili and not restricted to 
the tip.  These results showed that the TEM method was working 
and the results seen were not an artifact from the negative 
staining or fixation. 
Future direction in this area could include observations of 
various strains to examine pili characteristics such as length 
or abundance in strains express glycosylated versus non-
glycosylated pili.  Transmission electron micrographs could be 
taken and the pili could be counted and compared statistically.  
Other P. aeruginosa strains producing glycosylated pili such as 
577B (Castric and Deal, 1994) could be examined to extend the 
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results that the glycan is surface located over the entire 
fiber. 
 
B. Immunogenicity of pilin glycan 
 
1. Rabbit Studies 
 
This set of experiments was designed to determine the 
antibody titer produced by rabbits that were immunized with pure 
LPS-free pili.  Analysis of the antibodies produced would: 1) 
demonstrate whether or not the pili produce anti-LPS antibodies, 
2) produce a reagent that could be used for opsonization assays, 
and 3) determine whether IgG or IgM is the dominant antibody 
produced. 
The rabbits were immunized with pure LPS-free pili, however 
the antibodies produced were able to recognize LPS and pili.  
Presumably, this was due to an immune response to the pilin 
glycan that is identical in structure to the O-antigen repeating 
unit.  The results also show a high titer of IgG antibodies 
which indicates a T-dependent response.  A T-dependent response 
is desired since memory B cells would be produced against the 
antigen.  If O-antigen was used to immunize the rabbits, one 
would not expect to see high IgG antibody level because sugars 
normally don’t produce a T-dependent response.  Because the O-
antigen repeating unit was covalently bound to pilin protein, it 
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induced a T-dependent response which would not have been seen by 
vaccinating with O-antigen alone. 
The results could be beneficial to creating an effective 
pili-based vaccine since antibodies produced from immunization 
with glycosylated pili recognize LPS as well as pili.  It would 
be able to provide protection against all strains with O7 
antigen and pili like that of 1244. 
The high titer of antibodies produced could be due to the 
rabbits being immunized by many different routes such as 
intradermally, intramuscularly, and subcutaneously.  Utilizing 
various routes of immunization allowed for the antigen to spread 
over the entire body increasing the possibility for a higher 
amount of antibodies to be produced by the rabbit.  Another 
explanation for the high levels of antibodies is the number of 
times the rabbits were immunized along with the length of the 
experiment. 
Future studies could include a long-term protection study 
where mice would be immunized with pure LPS-free glycosylated 
pili. Following a long period of time, the pilus/LPS antibody 
levels would be determined by use of ELISA assays.  If high 
antibody levels are still present, this would suggest that 
memory response has taken place which is indicative of T-
dependence.  The preliminary results of a long-term protection 
study using mice are described in the next section. 
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2. Mouse Studies 
Marshall (masters thesis, 2001) was able to conclude that 
the pilus glycan was a major immunogenic region on the pili of 
P. aerguinosa 1244.  Preliminary evidence has been presented by 
Horzempa (unpublished) that the P. aeruginosa 1244 pilin glycan 
was a protective epitope.  This work was carried out using the 
intranasal mouse challenge model.  My studies were carried out 
to determine optimal conditions for immunization using this 
system.  These experiments were done for preliminary values in 
order to allow comprehensive protection studies in the future.  
The intranasal route of immunization was chosen for its ability 
to induce an IgA antibody response in respiratory secretions.  
This IgA response is significant in protecting against 
pneumonias caused by P. aeruginosa.  The intranasal route was 
also chosen because it can be administered in a painless manner. 
A fecal, serum, and BAL sample was collected for each mouse 
to determine the number and type of antibodies associated with 
each sample.  The fecal samples would contain antibodies that 
would be present in the gastrointestinal tract.  Because the 
antigen was processed via the mucosal route, high antibody 
levels should be present in the small intestine.  The serum 
samples were tested to determine the titer of antibodies 
produced by the mouse that were present in the blood.  The BAL 
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samples were tested to reveal how many antibodies were produced 
in the lungs, which was the site of immunization. 
Each sample was tested for IgG, IgA, and IgM antibodies by 
an ELISA assay.  These antibodies were chosen because the 
dominant antibody between IgG and IgM would suggest whether a T-
dependent or a T-independent response was being produced.  IgA 
antibodies are the primary mucosal antibodies.  The IgA titer 
would aid in determining the potential protection level acquired 
for this route of immunization. 
Overall, the antibody levels from the mice that were 
immunized with reaggregated pili were similar levels to the 
antibody levels of the sham-immunized mice.  The results show 
IgM antibodies in the serum, although it was thought that the 
levels would be much higher due to the antibody levels produced 
in the rabbit study.  IgM antibodies usually appear as one of 
the first host immune responses and then taper off as IgG 
antibodies are produced. This does correlate with the appearance 
of IgG antibodies in the serum samples of the 20µg reaggregated 
pili category as the IgM antibodies begin to disappear. 
No significant antibody levels could be detected in the BAL 
sample.  Previous studies (unpublished work by Held, Castric, 
and Cross) show a high titer of anti-pilin IgA antibodies found 
in the BAL sample when the mice were immunized with native pili 
intranasally.  In the current experiment, mice were immunized 
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with pure LPS-free reaggregated pili, and levels of anti-LPS 
antibodies were detected.  Whereas, Held et al. immunized mice 
with native pili that were possibly contaminated with low levels 
of LPS.  ELISA assays conducted by Held et al. utilized pili as 
the antigen therefore detecting anti-pilin antibodies.  My study 
detected anti-LPS antibodies as LPS was used as the antigen in 
the ELISA assays.  Future studies could be conducted using the 
mouse serum tested with pili as the antigen in an ELISA assay.  
This may reveal similar anti-pilin antibody levels to those 
discovered by Held et al.  LPS contamination could also have 
contributed to the high levels of antibodies (Pier, 1982) found 
by Held et al., since the antibodies that would react with O-
antigen would also react with pilin.   
Antibody titer levels in this study also differ from those 
found in the study by Comer et al. (2001).  Comer et al. 
immunized the mice by injecting them subcutaneously at the nap 
of the neck whereas the intranasal method was used for this 
study.  They found antibody levels significantly higher than the 
sham mice.  Therefore, the intranasal route of immunization 
induces a lesser antibody response than a subcutaneous 
immunization.  Marshall (masters thesis, 2001) also noticed that 
reaggregated pili induced lower levels of anti-LPS antibodies 
than native pili when introduced subcutaneously. 
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As previously mentioned, the low titer of antibodies could 
be due to the route of immunization used.  The mice were 
immunized intranasally which affects the mucosal system.  This 
kept the antigen contained in one area unlike the rabbits that 
were immunized in various places over the entire body.  Another 
explanation of the low levels of antibodies is the number of 
times the mice were immunized along with the length of the 
experiment.  At the most, the mice were only immunized twice 
with comparison to the rabbits that received six immunizations.  
This experiment only lasted two weeks while the rabbit 
immunizations continued for four months.  In addition, mice and 
rabbits do not always exhibit similar immune response when 
subjected to the same antigen (Priebe, G.P., 2002).  
The absence of antibodies that react with LPS may be due to 
the treatment used to produce the reaggregated pili.  The glycan 
may be buried inside the pilus when the fibers are reassembled, 
therefore leaving a decreased number of glycan epitopes 
available at the surface.  This hypothesis could be tested by 
taking transmission electron micrographs of the reaggregated 
pili with the glycan-specific monoclonal antibody and secondary 
antibody conjugated with gold particles.   
Since optimal conditions are not established for this 
system, further work in this area will include completing this 
protocol using native and nonglycosylated pili.  The mice will 
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be subject to the same immunization method to determine if there 
is a variation between glycosylated and nonglycosylated pili.  
This experiment could also be repeated using different 
immunization methods to determine which vaccine route provides 
the best response.   
C. Protection Studies 
Pseudomonas aeruginosa was tested for background levels of 
serum sensitivity and PMN (polymorphonuclear luekocyte) killing.  
Prior to opsonization studies, strains were tested for serum 
sensitivity.  If the strains were serum sensitive, then they 
could not be tested for opsonization. 
The mouse serum was used to test P. aeruginosa 1244 and 
1244.47 for any serum sensitivity.  This was done to determine 
if the system could detect killing by opsonization.  The results 
showed no killing of the bacteria in these assays which 
demonstrates that P. aeruginosa 1244 and 1244.47 are serum 
resistant.   
Since the strains tested were found to be serum resistant, 
phagocytosis assays were completed to determine if there was any 
opsonization when glycan-specific antibodies were present.  To 
ensure that the phagocytosis assay was working properly, it was 
tested with E.coli HB101 and P. aeruginosa 1244wbpL.  E.coli 
HB101 is a highly transformable strain which produces no O 
antigen (Sambrook et al., 1989).  P. aeruginosa 1244wbpL 
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produces non-glycosylated pili and also does not possess an O 
antigen (DiGiandomenico et al., 2002).  The presence of an O-
antigen layer is characteristic of cells that are resistant to 
phagocytosis.  As described in the results section, there was a 
decrease in viable cells indicating that the assay was working 
properly. 
P. aeruginosa 1244 and 1244.47 were tested for opsonization 
by the extent of PMN killing.  The results showed that there was 
no decrease in viable cell count indicating that there was no 
killing of the bacteria by the PMNs.  However, this was not the 
expected result since the function of the PMNs is to fight 
against the bacteria when it enters the body.  O-antigen on P. 
aeruginosa 1244 and 1244.47 could be causing the PMNs to be 
inactivated or unable to perform their function of killing the 
bacteria (Engels et al., 1985) since E. coli HB101 and P. 
aeruginosa 1244wbpL did have a decrease in viable cells.  
Another possibility of this assay not working could be due to 
weakened PMNs from the human volunteer whose immune system could 
be stressed.   
Results from the opsonization assay show that P. aeruginosa 
1244 is extremely resistant to phagocytosis which means that it 
should not be used in these types of assays.  Determination of 
protection by opsonization tests may not be practical.  Even 
though 30% rabbit serum concentration is high, this experiment 
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could be repeated using 100% serum concentration by resuspending 
P. aeruginosa 1244 and 1244.47 in the serum.  With a higher 
serum concentration, the bacteria may not remain resistant 
therefore a decrease in viable cells would be seen. 
Future experiments could be conducted using mouse serum 
rather than rabbit serum, or complement from other animals than 
those tested.  However, this assay utilized various types of 
complement such as baby rabbit and human, all with the same 
negative results, it is unlikely that using mouse complement 
would change the outcome. 
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